What is Afferent?
Headquartered in Woburn, Massachusetts, Afferent operates as a specialized entity within the pharmaceuticals industry. With a workforce of 20 to 49 employees and annual revenue ranging between 10M and 25M, the company maintains a focused market position. By leveraging its expertise in drug development and therapeutic innovation, Afferent has established itself as a key contributor to the regional biotech ecosystem, consistently demonstrating the capacity to translate complex scientific research into viable commercial solutions.
How much funding has Afferent raised?
Afferent has raised a total of $128.5M across 3 funding rounds:
Series C
$23.5M
Series E
$35M
Series F
$70M
Series C (2003): $23.5M with participation from Temasek Holdings, CLSA, West Deutsche Landesbank Girozentrale, GeneChem Inc., ABN AMRO Fund, Scottish Equity Partners, LDC, ProVen VCT, Avalon Ventures, and Technomark Medical Ventures
Series E (2007): $35M, investors not publicly disclosed
Series F (2009): $70M supported by MVM Life Science Partners, Ventech Solutions, Sectoral Asset Management, Ysios Capital Partners, and The Morningside Group
Key Investors in Afferent
MVM Life Science Partners
MVM Partners LLP invests in innovative healthcare companies, actively supporting businesses that enhance healthcare delivery through quality and cost-effective solutions.
Ysios Capital Partners
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, focusing on novel therapies for high unmet medical needs.
Sectoral Asset Management
Sectoral Asset Management focuses on developing and commercializing products intended to transform the treatment of complex medical conditions through advanced technological interventions.
What's next for Afferent?
With the recent capital injection, Afferent is well-positioned to transition into its next phase of enterprise-level growth. The strategic focus will likely center on expanding its clinical pipeline and strengthening its intellectual property portfolio. By aligning with high-caliber partners, the company is expected to enhance its operational efficiency and market reach, ultimately aiming to solidify its standing as a leader in pharmaceutical innovation. The current funding environment provides the necessary runway to navigate the complexities of late-stage development and potential market entry for its core therapeutic candidates.
See full Afferent company page
